Additionally, HDAC inhibitors have recently been shown to alter the TME immunogenicity of multiple different tumors in several ways, including the upregulating expression of tumor-associated antigens, increasing tumor cell MHC-II expression, inducing NK cell receptor and ligand expression, and decreasing immunosuppressive Tregs and MDSCs [148,149]. The gene discussed is HDAC9; the disease is neoplasm.